Suppr超能文献

侵袭性垂体肿瘤的最新进展

UPDATES IN AGGRESSIVE PITUITARY TUMORS.

作者信息

Burcea I, Poiana C

机构信息

"C.I. Parhon" National Institute of Endocrinology - Pituitary and Neuroendocrinology, Bucharest, Romania.

"C.I. Parhon" National Institute of Endocrinology - Endocrinology, Bucharest, Romania.

出版信息

Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):267-273. doi: 10.4183/aeb.2020.267.

DOI:10.4183/aeb.2020.267
PMID:33029249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7535899/
Abstract

Aggressive pituitary tumors lie between pituitary adenomas and carcinomas, displaying a particular behavior, with invasion, resistance to conventional therapy and early recurrence. The radiological grading, along with prognostic markers such as Ki-67 proliferation index, p53, MGMT and transcription factors are important factors in establishing the benign, aggressive, or malignant nature of pituitary tumors, with a more accurate treatment strategy. In this article, we report the novelties in defining, classifying, and managing aggressive pituitary tumors and their malignant potential, focusing on clinicopathological, histological, molecular and radiological data.

摘要

侵袭性垂体肿瘤介于垂体腺瘤和癌之间，表现出特殊的行为，具有侵袭性、对传统治疗的耐药性和早期复发的特点。放射学分级以及诸如Ki-67增殖指数、p53、MGMT和转录因子等预后标志物是确定垂体肿瘤的良性、侵袭性或恶性性质以及制定更准确治疗策略的重要因素。在本文中，我们报告了在定义、分类和管理侵袭性垂体肿瘤及其恶性潜能方面的新进展，重点关注临床病理、组织学、分子和放射学数据。

相似文献

1
UPDATES IN AGGRESSIVE PITUITARY TUMORS.侵袭性垂体肿瘤的最新进展
Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):267-273. doi: 10.4183/aeb.2020.267.
2
Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors.垂体瘤中Ki-67、P53和O-6-甲基鸟嘌呤-DNA甲基转移酶表达的预后效用评估。
J Lab Physicians. 2019 Oct-Dec;11(4):323-329. doi: 10.4103/JLP.JLP_76_19.
3
The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.Ki-67 增殖指数、P53 表达、有丝分裂指数和影像学肿瘤侵袭在垂体腺瘤中的预后作用。
Endocr Pathol. 2019 Mar;30(1):49-55. doi: 10.1007/s12022-018-9563-2.
4
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.免疫治疗在难治性垂体腺瘤和垂体癌中的进展。
Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020.
5
Aggressive pituitary tumors.侵袭性垂体肿瘤
Neuroendocrinology. 2015;101(2):87-104. doi: 10.1159/000371806. Epub 2015 Jan 5.
6
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.垂体腺瘤和癌中p53的表达：与侵袭性和肿瘤生长分数的相关性
Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1.
7
Refractory pituitary adenoma: a novel classification for pituitary tumors.难治性垂体腺瘤：一种垂体肿瘤的新分类
Oncotarget. 2016 Dec 13;7(50):83657-83668. doi: 10.18632/oncotarget.13274.
8
Aggressive pituitary adenomas--diagnosis and emerging treatments.侵袭性垂体腺瘤——诊断和新兴治疗方法。
Nat Rev Endocrinol. 2014 Jul;10(7):423-35. doi: 10.1038/nrendo.2014.64. Epub 2014 May 13.
9
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.侵袭性垂体腺瘤和腺癌是否为同一枚硬币的两面？病理学家解答临床医生的疑问。
Rev Endocr Metab Disord. 2020 Jun;21(2):243-251. doi: 10.1007/s11154-020-09562-9.
10
MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.促肾上腺皮质激素细胞瘤和癌的 MGMT 免疫组化表达。
Pituitary. 2010 Dec;13(4):367-79. doi: 10.1007/s11102-010-0249-0.

引用本文的文献

1
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach.特鲁利亚斯对垂体腺瘤的分级及术后肿瘤残留评估：多学科方法的重要性
Diagnostics (Basel). 2024 Jan 26;14(3):274. doi: 10.3390/diagnostics14030274.
2
Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas.比较蛋白质组学研究显示HINT-1在垂体腺瘤中的表达。
Diagnostics (Basel). 2021 Feb 17;11(2):330. doi: 10.3390/diagnostics11020330.

本文引用的文献

1
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.侵袭性垂体腺瘤和腺癌是否为同一枚硬币的两面？病理学家解答临床医生的疑问。
Rev Endocr Metab Disord. 2020 Jun;21(2):243-251. doi: 10.1007/s11154-020-09562-9.
2
Neuroimaging of aggressive pituitary tumors.侵袭性垂体瘤的神经影像学。
Rev Endocr Metab Disord. 2020 Jun;21(2):235-242. doi: 10.1007/s11154-020-09557-6.
3
Predictive model of surgical remission in acromegaly: age, presurgical GH levels and Knosp grade as the best predictors of surgical remission.肢端肥大症手术缓解的预测模型：年龄、术前 GH 水平和 Knosp 分级是手术缓解的最佳预测指标。
J Endocrinol Invest. 2021 Jan;44(1):183-193. doi: 10.1007/s40618-020-01296-4. Epub 2020 May 21.
4
Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas.针对侵袭性垂体肿瘤和癌的靶向系统性和肽类放射性配体治疗。
Rev Endocr Metab Disord. 2020 Jun;21(2):277-286. doi: 10.1007/s11154-020-09554-9.
5
The epidemiology of aggressive pituitary tumors (and its challenges).侵袭性垂体瘤的流行病学（及其挑战）。
Rev Endocr Metab Disord. 2020 Jun;21(2):209-212. doi: 10.1007/s11154-020-09556-7.
6
Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors.GATA-3 表达在垂体神经内分泌肿瘤（PitNET）转录因子分析中的应用。
Endocr Pathol. 2020 Jun;31(2):150-155. doi: 10.1007/s12022-020-09615-4.
7
Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives.替莫唑胺治疗侵袭性垂体肿瘤——当前认识和未来展望。
Rev Endocr Metab Disord. 2020 Jun;21(2):263-276. doi: 10.1007/s11154-020-09551-y.
8
How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.2020年如何对垂体神经内分泌肿瘤（PitNET）进行分类。
Cancers (Basel). 2020 Feb 22;12(2):514. doi: 10.3390/cancers12020514.
9
Radiation techniques in aggressive pituitary tumours and carcinomas.侵袭性垂体瘤和癌的放射治疗技术。
Rev Endocr Metab Disord. 2020 Jun;21(2):287-292. doi: 10.1007/s11154-020-09543-y.
10
Aggressive pituitary tumors in the young and elderly.年轻人和老年人中的侵袭性垂体肿瘤。
Rev Endocr Metab Disord. 2020 Jun;21(2):213-223. doi: 10.1007/s11154-019-09534-8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验